Brachial artery Flow Mediated Dilation (FMD)
The endothelial function will be assessed using the non-invasive ultrasound technique of flow mediated dilatation of the brachial artery. FMD measure is the percentage of dilation of brachial artery in response to a reactive hyperaemia induced by the release of a transient occlusion of the brachial artery realized.
Brachial artery Flow Mediated Dilation (FMD)
The endothelial function will be assessed using the non-invasive ultrasound technique of flow mediated dilatation of the brachial artery. FMD measure is the percentage of dilation of brachial artery in response to a reactive hyperaemia induced by the release of a transient occlusion of the brachial artery realized between T-30min to T300min.
Brachial artery Flow Mediated Dilation (FMD)
The endothelial function will be assessed using the non-invasive ultrasound technique of flow mediated dilatation of the brachial artery. FMD measure is the percentage of dilation of brachial artery in response to a reactive hyperaemia induced by the release of a transient occlusion of the brachial artery realized between T-30min to T300min.
Brachial artery Flow Mediated Dilation (FMD)
The endothelial function will be assessed using the non-invasive ultrasound technique of flow mediated dilatation of the brachial artery. FMD measure is the percentage of dilation of brachial artery in response to a reactive hyperaemia induced by the release of a transient occlusion of the brachial artery realized between T-30min to T300min.
Brachial artery Flow Mediated Dilation (FMD)
The endothelial function will be assessed using the non-invasive ultrasound technique of flow mediated dilatation of the brachial artery. FMD measure is the percentage of dilation of brachial artery in response to a reactive hyperaemia induced by the release of a transient occlusion of the brachial artery realized between T-30min to T300min.
Brachial artery Flow Mediated Dilation (FMD)
The endothelial function will be assessed using the non-invasive ultrasound technique of flow mediated dilatation of the brachial artery. FMD measure is the percentage of dilation of brachial artery in response to a reactive hyperaemia induced by the release of a transient occlusion of the brachial artery realized between T-30min to T300min.
Brachial artery Flow Mediated Dilation (FMD)
The endothelial function will be assessed using the non-invasive ultrasound technique of flow mediated dilatation of the brachial artery. FMD measure is the percentage of dilation of brachial artery in response to a reactive hyperaemia induced by the release of a transient occlusion of the brachial artery realized between T-30min to T300min.
Brachial artery Flow Mediated Dilation (FMD)
The endothelial function will be assessed using the non-invasive ultrasound technique of flow mediated dilatation of the brachial artery. FMD measure is the percentage of dilation of brachial artery in response to a reactive hyperaemia induced by the release of a transient occlusion of the brachial artery realized between T-30min to T300min.
Brachial artery Flow Mediated Dilation (FMD)
The endothelial function will be assessed using the non-invasive ultrasound technique of flow mediated dilatation of the brachial artery. FMD measure is the percentage of dilation of brachial artery in response to a reactive hyperaemia induced by the release of a transient occlusion of the brachial artery realized between T-30min to T300min.
Rest flow by Flowmetry Laser Doppler (FLD)
Vascular endothelial function in the micro-vascular compartment will be assessed using the measurement of the rest flow using laser-Doppler system at the level of the skin of the hand realized between T-30min to T300min.
Occlusion area by FLD
Vascular endothelial function in the micro-vascular compartment will be assessed using the measurement of the occlusion area using laser-Doppler system at the level of the skin of the hand by following the response to a reactive hyperaemia induced by the release of a transient occlusion of the brachial artery (same stimulus as for FMD measurement) realized between T-30min to T300min.
Hyperaemia area by FLD
Vascular endothelial function in the micro-vascular compartment will be assessed using the measurement of the hyperaemia area using laser-Doppler system at the level of the skin of the hand by following the response to a reactive hyperaemia induced by the release of a transient occlusion of the brachial artery (same stimulus as for FMD measurement) realized between T-30min to T300min.
Hyperaemia area / occlusion area ratio by FLD
Vascular endothelial function in the micro-vascular compartment will be assessed using the ratio hyperaemia area / occlusion area determined by FLD realized between T-30min to T300min.
Maximal flow by FLD
Vascular endothelial function in the micro-vascular compartment will be assessed using the measurement of the maximal flow using laser-Doppler system at the level of the skin of the hand by following the response to a reactive hyperaemia induced by the release of a transient occlusion of the brachial artery (same stimulus as for FMD measurement) realized between T-30min to T300min.
Hyperaemia half time by FLD
Vascular endothelial function in the micro-vascular compartment will be assessed using the measurement of the hyperaemia half time using laser-Doppler system at the level of the skin of the hand by following the response to a reactive hyperaemia induced by the release of a transient occlusion of the brachial artery (same stimulus as for FMD measurement) realized between T-30min to T300min.
Reactive Hyperemia - Peripheral Arterial Tonometry (RH-PAT)
Reactive hyperemia index (RHI) assessed by reactive hyperemia-peripheral arterial tonometry (RH-PAT) expressed as a percentage measures pulsatile fluctuations in digital volume in response to a reactive hyperaemia induced by the release of a transient occlusion realized between T-30min to T300min.
Plasma nitrite dosage
Determination of nitrite plasma concentration (µmol/L) (a biomarker of endothelial activation) between T-90min to T360min.
Urine nitrite dosage
Determination of nitrite urine concentration (µmol/L) (a biomarker of endothelial activation) between T-60min to T250min.
Plasma nitrate dosage
Determination of nitrate plasma concentration (µmol/L) (a biomarker of endothelial activation) between T-90min to T360min.
Urine nitrate dosage
Determination of nitrate urine concentration (µmol/L) (a biomarker of endothelial activation) between T-60min to T250min.
Plasma creatinine dosage
Determination of creatinine plasma concentration (µmol/L) (a biomarker of chronic kidney disease) between T-90min to T360min.
Urine creatinine dosage
Determination of creatinine urine concentration (µmol/L) (a biomarker of chronic kidney disease) between T-60min to T250min.
Plasma malondialdehyde (MDA) dosage
Determination of MDA plasma concentration (nmol/L) (a biomarker of oxidative stress) between T-90min to T360min.
Urine malondialdehyde (MDA) dosage
Determination of MDA urine concentration (nmol/L) (a biomarker of oxidative stress) between T-60min to T250min.
Plasma asymmetric dimethylarginine (ADMA) dosage
Determination of ADMA plasma concentration (µmol/L) (a biomarker of cardiovascular disease) between T-90min to T360min.
Urine asymmetric dimethylarginine (ADMA) dosage
Determination of ADMA urine concentration (µmol/L) (a biomarker of cardiovascular disease) between T-60min to T250min.
Plasma symmetric dimethylarginine (SDMA) dosage
Determination of SDMA plasma concentration (µmol/L) (a biomarker of cardiovascular disease) between T-90min to T360min.
Urine symmetric dimethylarginine (SDMA) dosage
Determination of SDMA urine concentration (µmol/L) (a biomarker of cardiovascular disease) between T-60min to T250min.
Plasma acetyl-lysine dosage
Determination of acetyl-lysine plasma concentration (µmol/L) (a biomarker of vascular oxidative stress) between T-90min to T360min.
Urine symmetric acetyl-lysine dosage
Determination of acetyl-lysine urine concentration (µmol/L) (a biomarker of vascular oxidative stress) between T-60min to T250min
Plasma N-epsilon-carboxy-methyl lysine (CML) dosage
Determination of CML plasma concentration (pg/mL) (a biomarker of oxidative stress) between T-90min to T360min.
Urine N-epsilon-carboxy-methyl lysine (CML) dosage
Determination of CML urine concentration (pg/mL) (a biomarker of oxidative stress) between T-60min to T250min.
Plasma N-epsilon-carboxy-ethyl lysine (CEL) dosage
Determination of CEL plasma concentration (pg/mL) (a biomarker of oxidative stress) between T-90min to T360min.
Urine N-epsilon-carboxy-ethyl lysine (CEL) dosage
Determination of CEL urine concentration (pg/mL) (a biomarker of oxidative stress) between T-60min to T250min.
Plasma alanine dosage
Determination of alanine plasma concentration (µmol/L) between T-90min to T360min.
Urine alanine dosage
Determination of alanine urine concentration (µmol/L) between T-60min to T250min.
Plasma arginine dosage
Determination of arginine plasma concentration (µmol/L) between T-90min to T360min
Urine arginine dosage
Determination of arginine urine concentration (µmol/L) between T-60min to T250min.
Plasma asparagine dosage
Determination of asparagine plasma concentration (µmol/L) between T-90min to T360min
Urine asparagine dosage
Determination of asparagine urine concentration (µmol/L) between T-60min to T250min.
Plasma aspartic acid dosage
Determination of aspartic acid plasma concentration (µmol/L) between T-90min to T360min.
Urine aspartic acid dosage
Determination of aspartic acid urine concentration (µmol/L) between T-60min to T250min.
Plasma cysteine dosage
Determination of cysteine plasma concentration (µmol/L) between T-90min to T360min.
Urine cysteine dosage
Determination of cysteine urine concentration (µmol/L) between T-60min to T250min
Plasma glutamic acid dosage
Determination of glutamic acid plasma concentration (µmol/L) between T-90min to T360min.
Urine glutamic acid dosage
Determination of glutamic acid urine concentration (µmol/L) between T-60min to T250min.
Plasma glutamine dosage
Determination of glutamine plasma concentration (µmol/L) between T-90min to T360min
Urine glutamine dosage
Determination of glutamine urine concentration (µmol/L) between T-60min to T250min.
Plasma glycine dosage
Determination of glycine plasma concentration (µmol/L) between T-90min to T360min
Urine glycine dosage
Determination of glycine urine concentration (µmol/L) between T-60min to T250min
Plasma histidine dosage
Determination of histidine plasma concentration (µmol/L) between T-90min to T360min
Urine histidine dosage
Determination of histidine urine concentration (µmol/L) between T-60min to T250min
Plasma isoleucine dosage
Determination of isoleucine plasma concentration (µmol/L) between T-90min to T360min.
Urine isoleucine dosage
Determination of isoleucine urine concentration (µmol/L) between T-60min to T250min.
Plasma leucine dosage
Determination of leucine plasma concentration (µmol/L) between T-90min to T360min.
Urine leucine dosage
Determination of leucine urine concentration (µmol/L) between T-60min to T250min.
Plasma lysine dosage
Determination of lysine plasma concentration (µmol/L) between T-90min to T360min.
Urine lysine dosage
Determination of lysine urine concentration (µmol/L) between T-60min to T250min.
Plasma methionine dosage
Determination of methionine plasma concentration (µmol/L) between T-90min to T360min.
Urine methionine dosage
Determination of methionine urine concentration (µmol/L) between T-60min to T250min.
Plasma phenylalanine dosage
Determination of phenylalanine plasma concentration (µmol/L) between T-90min to T360min.
Urine phenylalanine dosage
Determination of phenylalanine urine concentration (µmol/L) between T-60min to T250min.
Plasma proline dosage
Determination of proline plasma concentration (µmol/L) between T-90min to T360min.
Urine proline dosage
Determination of proline urine concentration (µmol/L) between T-60min to T250min.
Plasma serine dosage
Determination of serine plasma concentration (µmol/L) between T-90min to T360min.
Urine serine dosage
Determination of serine urine concentration (µmol/L) between T-60min to T250min.
Plasma threonine dosage
Determination of threonine plasma concentration (µmol/L) between T-90min to T360min.
Urine threonine dosage
Determination of threonine urine concentration (µmol/L) between T-60min to T250min.
Plasma tryptophan dosage
Determination of tryptophan plasma concentration (µmol/L) between T-90min to T360min.
Urine tryptophan dosage
Determination of tryptophan urine concentration (µmol/L) between T-60min to T250min.
Plasma tyrosine dosage
Determination of tyrosine plasma concentration (µmol/L) between T-90min to T360min.
Urine tyrosine dosage
Determination of tyrosine urine concentration (µmol/L) between T-60min to T250min.
Plasma valine dosage
Determination of tyrosine plasma concentration (µmol/L) between T-90min to T360min.
Urine valine dosage
Determination of tyrosine urine concentration (µmol/L) between T-60min to T250min.
Plasma Interleukin 6 (IL-6) dosage
Determination of IL-6 plasma concentration (pg/ml) (a biomarker of inflammation and oxidative stress) between T-90min to T360min
Plasma Interleukin 1 bêta (IL-1β) dosage
Determination of IL-1β plasma concentration (pg/ml) (a biomarker of inflammation and oxidative stress) between T-90min to T360min.
Plasma Monocyte Chemoattractant Protein-1 (MCP-1) dosage
Determination of MCP-1 plasma concentration (pg/ml) (a biomarker of inflammation and oxidative stress) between T-90min to T360min.
Plasma Tumor Necrosis Factor alpha (TNFα) dosage
Determination of TNFα plasma concentration (pg/ml) (a biomarker of inflammation and oxidative stress) between T-90min to T360min.
Plasma InterCellular Adhesion Molecule 1 (ICAM-1) dosage
Determination of ICAM-1 plasma concentration (ng/ml) (a biomarker of endothelial activation) between T-90min to T360min.
Plasma E-Selectine dosage
Determination of E-Selectine plasma concentration (ng/ml) (a biomarker of endothelial activation) between T-90min to T360min.
Transcriptome Sequencing of Peripheral Blood Mononuclear Cells
Transcriptomic Analysis to quantify sets of genes involved in endothelial activation, oxidative stress, inflammation and cytokine expression between T-90 min to T360min.
Metabolome Sequencing of Plasma
Untargeted Metabolomics to identify and quantify molecules involved in endothelial activation, oxidative stress, inflammation and cytokine expression between T-90 min to T360min.
Plasma Glucose dosage
Determination of glucose plasma concentration (mg/dl) between T-90min to T360min.
Plasma triglycerides dosage
Determination of triglycerides plasma concentration (mg/dl) between T-90min to T360min.
Plasma insulin dosage
Determination of insulin plasma concentration (pmol/L) between T-90min to T360min
blood Peripheral Blood Mononuclear Cells (PBMC) count
Determination of PBMC count (/mm3) and phenotyping between T-90min to T360min.
PBMC production of Reactive Oxygen Species (ROS)
Assessment of the ROS level (between T-90min to T360min) produced by isolated PBMC following oxidative stress induction.
Questionnaire of acceptability
Acceptability was assessed by a 9-point time scale where "1" means a very poor acceptability and "9" means a very good acceptability.